European guidelines back use of Sanofi's Multaq
by on Aug.29, 2010, under Health and Fitness
Sanofi-Aventis's new heart rhythm drug Multaq should be considered as a first-line treatment option for patients with atrial fibrillation, a common arrhythmia, according to medical guidelines released on Sunday.
View full post on Yahoo! Health News
